Nicholas Lodato, PhD

Nicholas Lodato, PhD, has extensive work experience in the field of biosciences, starting with their current role as Principal Scientist at Pillar Biosciences Incorporated since March 2023. Prior to this, they held the positions of Senior Scientist, Scientist II, and Scientist I at the same company, with their tenure spanning from October 2017 to June 2021.

Before joining Pillar Biosciences Incorporated, Dr. Lodato was a PhD Candidate in Cell and Molecular Biology at Boston University from September 2009 to August 2017. During their time there, they used next-gen sequencing (NGS) to study drug metabolizing enzyme gene expression and made significant discoveries related to non-coding RNA transcripts and DNA regulatory elements. Their research on sex differences in response to drug treatments led to a first-author publication.

Prior to their doctoral studies, Dr. Lodato worked as an Associate Biologist at AD4-Pharma, a small startup biotech company, from March 2008 to August 2009. In this role, they played multiple roles and contributed to the development of a method to identify candidate compounds as novel EGFR inhibitors. Their work resulted in a patent application. Nicholas also developed cell culture-based assays for high throughput screening.

Before joining AD4-Pharma, Dr. Lodato worked as an Analytical Chemist at Schering-Plough from July 2007 to March 2008. Nicholas started their professional career as an Undergraduate Researcher at Widener University from June 2006 to May 2007, where they worked on two separate projects, one of which resulted in an undergraduate senior thesis in microbiology.

Dr. Lodato also gained experience through a Chemistry Internship at Chemettal Oakite in June 2006.

Overall, Dr. Nicholas Lodato's work experience showcases their expertise in biosciences, with a focus on next-gen sequencing, drug metabolism, and the development of innovative methods in the field.

Nicholas Lodato, PhD, completed their Bachelor of Science (BS) in Biology from Widener University from 2003 to 2007. Subsequently, they pursued their higher education at Boston University, where they obtained their Doctor of Philosophy (Ph.D.) in Cell/Cellular and Molecular Biology from 2009 to 2017.